Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma

NCT00002463 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT00002463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
February 28, 1989
Completion date
January 31, 2008
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain and central nervous system tumors